Biotech Group Welcomes Budget 2026 Life Sciences Measures
BIOTECanada backed proposed federal tax support and funding aimed at strengthening Canada's life sciences sector.
Updated on Nov. 6, 2026 in Biotech
Live Poll
Should the federal government spend more on biotech and life sciences research?
BIOTECanada welcomed measures in Budget 2026 intended to strengthen Canada's life sciences sector. The budget proposes expanded SR&ED tax support covering certain regulatory approval and intellectual property costs.
Why it matters
The proposed changes target costs that can slow commercialization of biotech and pharmaceutical products in Canada. The measures follow recommendations from the Pharmaceutical and Life Sciences Sector Task Force, which BIOTECanada participated in.
Budget 2026 projects $930 million over five years in expanded SR&ED tax support, and adds $1 billion over six years to the Strategic Response Fund. The Task Force's 39 recommendations remain under federal assessment.
The players
BIOTECanada
BIOTECanada is the national industry association representing biotechnology companies, with over 200 member companies across Canada.
The details
Budget 2026 expands SR&ED eligibility to cover certain regulatory approval and intellectual property costs. It also introduces the proposed Canada Growth Incentive to encourage investment in Canadian companies, and identifies biomanufacturing as an area to receive Strategic Response Fund support.
Timeline
November 6, 2026: BIOTECanada issued its statement welcoming the budget measures.
Over five years: expanded SR&ED support is projected to provide $930 million.
Over six years: the additional $1 billion for the Strategic Response Fund is scheduled.
Big Picture
Budget 2026's life sciences measures respond in part to the 39 recommendations of the Pharmaceutical and Life Sciences Sector Task Force, on which BIOTECanada served. The federal government says it is still assessing the remaining recommendations.
Expanded SR&ED support could lower the cost of certain regulatory approval and intellectual property work for Canadian biotech firms. Readers following drug development costs may see these changes affect how quickly new products reach the market.
The takeaway
Budget 2026 signals federal intent to lower certain development costs for life sciences companies in Canada. Progress will depend on how the government acts on the remaining Task Force recommendations.
Further reading
For broader coverage of the sector, see Biotech news in Canada.
Source note: This article includes information reported by Sault Star.
Live Poll
Should the federal government spend more on biotech and life sciences research?
